Cardiff Oncology furnishes Feb 2026 corporate presentation; no material news

Cardiff Oncology, Inc.

Corporate slide presentation furnished as Exhibit 99.1 for investor meetings.
Presentation highlights onvansertib development pipeline and opportunity.
No financial results, guidance, or operational milestones disclosed.
Routine Regulation FD disclosure; no material changes to business.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.